MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy

TY - JOUR

T1 - MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy

AU - Lalla, Rajesh V

AU - Bowen, Joanne

AU - Barasch, Andrei

AU - Elting, Linda

AU - Epstein, Joel

AU - Keefe, Dorothy M

AU - McGuire, Deborah B

AU - Migliorati, Cesar

AU - Nicolatou-Galitis, Ourania

AU - Peterson, Douglas E

AU - Raber-Durlacher, Judith E

AU - Sonis, Stephen T

AU - Elad, Sharon

AU - Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO)

AU - Jensen, Siri Beier

N1 - © 2014 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.

PY - 2014/5/15

Y1 - 2014/5/15

N2 - BACKGROUND: Mucositis is a highly significant, and sometimes dose-limiting, toxicity of cancer therapy. The goal of this systematic review was to update the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) Clinical Practice Guidelines for mucositis.METHODS: A literature search was conducted to identify eligible published articles, based on predefined inclusion/exclusion criteria. Each article was independently reviewed by 2 reviewers. Studies were rated according to the presence of major and minor flaws as per previously published criteria. The body of evidence for each intervention, in each treatment setting, was assigned a level of evidence, based on previously published criteria. Guidelines were developed based on the level of evidence, with 3 possible guideline determinations: recommendation, suggestion, or no guideline possible.RESULTS: The literature search identified 8279 papers, 1032 of which were retrieved for detailed evaluation based on titles and abstracts. Of these, 570 qualified for final inclusion in the systematic reviews. Sixteen new guidelines were developed for or against the use of various interventions in specific treatment settings. In total, the MASCC/ISOO Mucositis Guidelines now include 32 guidelines: 22 for oral mucositis and 10 for gastrointestinal mucositis. This article describes these updated guidelines.CONCLUSIONS: The updated MASCC/ISOO Clinical Practice Guidelines for mucositis will help clinicians provide evidence-based management of mucositis secondary to cancer therapy.

AB - BACKGROUND: Mucositis is a highly significant, and sometimes dose-limiting, toxicity of cancer therapy. The goal of this systematic review was to update the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) Clinical Practice Guidelines for mucositis.METHODS: A literature search was conducted to identify eligible published articles, based on predefined inclusion/exclusion criteria. Each article was independently reviewed by 2 reviewers. Studies were rated according to the presence of major and minor flaws as per previously published criteria. The body of evidence for each intervention, in each treatment setting, was assigned a level of evidence, based on previously published criteria. Guidelines were developed based on the level of evidence, with 3 possible guideline determinations: recommendation, suggestion, or no guideline possible.RESULTS: The literature search identified 8279 papers, 1032 of which were retrieved for detailed evaluation based on titles and abstracts. Of these, 570 qualified for final inclusion in the systematic reviews. Sixteen new guidelines were developed for or against the use of various interventions in specific treatment settings. In total, the MASCC/ISOO Mucositis Guidelines now include 32 guidelines: 22 for oral mucositis and 10 for gastrointestinal mucositis. This article describes these updated guidelines.CONCLUSIONS: The updated MASCC/ISOO Clinical Practice Guidelines for mucositis will help clinicians provide evidence-based management of mucositis secondary to cancer therapy.

KW - Amifostine

KW - Analgesics

KW - Anti-Infective Agents

KW - Anti-Inflammatory Agents

KW - Anti-Ulcer Agents

KW - Antineoplastic Agents

KW - Cryotherapy

KW - Cytokines

KW - Esophagitis

KW - Evidence-Based Medicine

KW - Humans

KW - Hyperbaric Oxygenation

KW - Intercellular Signaling Peptides and Proteins

KW - Laser Therapy, Low-Level

KW - Mucositis

KW - Neoplasms

KW - Oral Hygiene

KW - Phototherapy

KW - Proctitis

KW - Protective Agents

KW - Radiation-Protective Agents

KW - Radiotherapy

KW - Stomatitis

KW - Sucralfate

U2 - 10.1002/cncr.28592

DO - 10.1002/cncr.28592

M3 - Journal article

C2 - 24615748

SN - 0008-543X

VL - 120

SP - 1453

EP - 1461

JO - Cancer

JF - Cancer

IS - 10

ER -